Semaglutide, a long-acting GLP-1 agonist, exhibited a sustained weight decrease of approximately 15% of body weight in clinical studies, whereas tirzepatide, a combination GIP/GLP-1 agonist, attained a weight loss of up to 22.5% in the SURMOUNT trials [36,37]
Think of peptides as biological messengers that tell your cells what to do
Gastroenterology 142 (Suppl
In earlier studies, retatrutide reduced liver fat by more than 80% in people with metabolic fatty liver disease, with most participants no longer meeting diagnostic thresholds
Frontline Formulations L-Carnitine is designed for consistent daily use and fits well into structured nutrition and training programs focused on body composition and performance
are cardiorenal protective